Keyphrases
Acute Myeloid Leukemia
75%
Overall Survival
65%
Chemotherapy
54%
Tumor
45%
Phase II Trial
44%
Phase II Study
42%
Chronic Myeloid Leukemia
37%
Breast Cancer
36%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
35%
Clinical Trials
34%
Interferon-α (IFN-α)
33%
Progression-free Survival
32%
Confidence Interval
32%
Prostate Cancer
32%
Metastatic Breast Cancer
30%
In Cancer
29%
Hematological Malignancies
28%
Relapsed or Refractory
24%
Myelodysplastic Syndrome
24%
Leukemia
24%
Oncology
23%
Acute Promyelocytic Leukemia
23%
Hazard Ratio
22%
Melanoma
22%
Complete Remission
21%
Targeted Therapy
21%
Chronic Lymphocytic Leukemia
21%
NCCN Guidelines
20%
Apoptosis
20%
Non-small Cell Lung Cancer (NSCLC)
19%
Circulating Tumor Cells
18%
Complete Response
18%
Diffuse Large B-cell Lymphoma (DLBCL)
18%
Cyclophosphamide
17%
Inflammatory Breast Cancer
17%
Multiple Myeloma
17%
Rituximab
17%
Newly Diagnosed
17%
T Cells
17%
Acute Lymphoblastic Leukemia
17%
Partial Response
17%
Adverse Events
17%
Clinical Practice Guidelines
16%
Clinical Outcomes
16%
Malignancy
16%
Programmed Death-ligand 1 (PD-L1)
15%
Colorectal Cancer
15%
Response Rate
15%
Relapsed or Refractory Acute Myeloid Leukemia
15%
Disease Progression
15%
High Risk
15%
5-fluorouracil (5-FU)
15%
Docetaxel
15%
Phase I Study
15%
Eastern Cooperative Oncology Group
14%
Lymphoma
14%
Androgen Deprivation Therapy
14%
Cancer Cells
14%
Doxorubicin
14%
Non-Hodgkin Lymphoma
14%
Hepatocellular Carcinoma
13%
Placebo
13%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
13%
United States
13%
All-trans Retinoic Acid
13%
Median Overall Survival
13%
CD95
13%
Disease-free Survival
13%
Myeloproliferative Neoplasms
13%
Bone Marrow
13%
Ovarian Cancer
13%
Metastatic Disease
12%
Overall Response Rate
12%
Adjuvant Therapy
12%
Tumor Cells
12%
Cisplatin
12%
Gemcitabine
12%
Quality of Life
12%
Neutropenia
12%
Randomized Phase II Trial
12%
Treatment Options
11%
Phosphorylation
11%
High Dose
11%
Human Epidermal Growth Factor Receptor 2 (HER2)
11%
Graft-versus-host Disease (GvHD)
11%
Systemic Therapy
11%
Stable Disease
11%
Radiation Therapy
11%
Lung Cancer
11%
Immune Checkpoint Inhibitors
11%
Thrombocytopenia
11%
Cytarabine
11%
Cancer Patients
11%
Paclitaxel
11%
Bevacizumab
11%
Solid Tumors
11%
Leukemia Patients
11%
Imatinib
11%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
11%
Gene Expression
11%
Medicine and Dentistry
Diseases
100%
Neoplasm
81%
Malignant Neoplasm
79%
Chemotherapy
65%
Overall Survival
64%
Breast Cancer
57%
Acute Myeloid Leukemia
56%
Oncology
49%
Prostate Cancer
41%
Clinical Trial
37%
Progression Free Survival
32%
Metastatic Carcinoma
28%
Melanoma
26%
Hematopoietic Cell
24%
Immunotherapy
23%
Myelodysplastic Syndrome
21%
Cancer
21%
Radiation Therapy
21%
Adverse Event
21%
Targeted Therapy
20%
Cancer Cell
19%
Metastatic Breast Cancer
19%
Leukemia
18%
Acute Promyelocytic Leukemia
18%
Transplantation
18%
Non Small Cell Lung Cancer
18%
Chronic Myelogenous Leukemia
17%
Non-Hodgkin Lymphoma
17%
Hematologic Malignancy
17%
Recurrent Disease
16%
Hazard Ratio
16%
Circulating Tumor Cell
16%
Ovarian Cancer
16%
Acute Lymphoblastic Leukemia
16%
Biological Marker
16%
T Cell
16%
Arm
15%
Rituximab
15%
Multiple Myeloma
15%
Programmed Cell Death
14%
Drug Megadose
14%
Diffuse Large B-Cell Lymphoma
14%
Phase II Trials
14%
Systemic Therapy
14%
Cell Transplantation
14%
Hepatocellular Carcinoma
14%
Inflammatory Breast Cancer
14%
B-Cell Chronic Lymphocytic Leukemia
14%
Quality of Life
13%
Immunity
13%
Adjuvant Therapy
12%
Cancer Therapy
12%
Surgery
12%
Lung Cancer
11%
B Cell
11%
Yttrium 90
11%
Pancreas Cancer
11%
Colon Carcinoma
11%
Disease Free Survival
11%
Cyclophosphamide
11%
Survival Rate
11%
Doxorubicin
11%
Colorectal Carcinoma
11%
In Vitro
10%
Platelet
10%
Hodgkin's Lymphoma
10%
Tumor Cell
10%
Interferon
10%
Placebo
10%
Radioembolization
10%
Nivolumab
9%
Tumor Progression
9%
Clinician
9%
Cytarabine
9%
Acute Leukemia
9%
Immune Checkpoint Inhibitor
9%
Epidermal Growth Factor Receptor
9%
Disease Exacerbation
9%
Tretinoin
9%
Receptor
9%
Diagnosis
9%
Gemcitabine
9%
Arsenic Trioxide
9%
Paclitaxel
8%
Imatinib
8%
Prognostic Factor
8%
Infection
8%
Myeloproliferative Neoplasm
8%
Clear Cell Renal Cell Carcinoma
8%
Germ Cell
8%
Signal Transduction
8%
Minimal Residual Disease
8%
Bleeding
8%
Castration Resistant Prostate Cancer
8%
Fluorouracil
8%
Clinical Oncology
7%
Solid Malignant Neoplasm
7%
Cisplatin
7%
Myeloma
7%
Tyrosine-Kinase Inhibitor
7%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
91%
Disease
86%
Neoplasm
82%
Chemotherapy
76%
Overall Survival
62%
Acute Myeloid Leukemia
57%
Breast Cancer
48%
Prostate Cancer
41%
Progression Free Survival
38%
Clinical Trial
38%
Remission
31%
Adverse Event
30%
Chronic Myeloid Leukemia
27%
Leukemia
22%
Metastatic Breast Cancer
22%
Myelodysplastic Syndrome
22%
Phase II Trials
22%
Imatinib
19%
Melanoma
19%
Promyelocytic Leukemia
18%
Interferon
18%
Solid Malignant Neoplasm
17%
Nonhodgkin Lymphoma
17%
Immunotherapy
17%
Rituximab
17%
Hematologic Malignancy
17%
Cytarabine
17%
Placebo
17%
Paclitaxel
16%
Chronic Lymphatic Leukemia
16%
Non Small Cell Lung Cancer
15%
Castration Resistant Prostate Cancer
15%
Biological Marker
14%
Docetaxel
14%
Doxorubicin
14%
Fluorouracil
14%
Cyclophosphamide
14%
Androgen
14%
Multiple Myeloma
14%
Receptor
13%
Acute Lymphoblastic Leukemia
13%
Metastasis
12%
Pharmacokinetics
12%
Recurrent Disease
12%
Cisplatin
12%
Ovary Cancer
11%
Protein Tyrosine Kinase Inhibitor
11%
Retinoic Acid
11%
Epidermal Growth Factor Receptor
11%
Survival Rate
11%
Gemcitabine
10%
Colorectal Carcinoma
10%
Renal Cell Carcinoma
10%
Disease Exacerbation
10%
Colon Carcinoma
10%
Bevacizumab
10%
Pancreas Cancer
10%
Yttrium 90
10%
Neutropenia
10%
Phosphotransferase
9%
Combination Therapy
9%
Lung Cancer
9%
Diffuse Large B Cell Lymphoma
9%
Cytokine
8%
Liver Cell Carcinoma
8%
Inflammatory Breast Cancer
8%
Prostate Specific Antigen
8%
Maximum Tolerated Dose
8%
Fludarabine
8%
Monotherapy
8%
Tumor Growth
8%
Thrombocytopenia
8%
Diarrhea
8%
Nivolumab
8%
Disease Free Survival
8%
Gamma Urogastrone
8%
Nilotinib
8%
Tolerability
8%
Interleukin 2
8%
Arsenite
7%
Arsenous Acid
7%
Anemia
7%
Carboplatin
7%
Anthracycline
7%
Acute Leukemia
7%
Pancreas Adenocarcinoma
7%
Epidermal Growth Factor Receptor 2
7%
Monoclonal Antibody
7%
Bortezomib
7%
Metastatic Colorectal Cancer
7%
Chemoradiation Therapy
7%
Philadelphia 1 Chromosome
7%
Hodgkin Disease
7%
Myeloma
7%
Vincristine
6%
Infection
6%
Ipilimumab
6%
Etoposide
6%
Bleeding
6%
Metastatic Melanoma
6%